Cato BioVentures

About The Fund

Cato BioVentures is the venture capital affiliate of the life sciences regulatory and clinical contract research organization, Cato Research. With a focus on the biotech and pharmaceutical industries, the fund operates as an adept investor across all developmental stages of a company. They exhibit expertise in the equity investment space, predominantly within the realms of BioTech, Medical Devices (& Hospital Services), and Life Science sectors. Cato BioVentures has established itself as a collaborative partner for entrepreneurs, academic institutions, and a diverse range of biotech and pharmaceutical enterprises, aiming to shepherd successful product development programs to fruition. Their investment strategy demonstrates flexibility, engaging in both private and public company funding, with investments typically ranging from a minimum of $1,590,000 to a maximum of $1,700,000. Cato BioVentures brings to the table a rare blend of long-term investment philosophy and a robust suite of services to assist portfolio companies in areas such as clinical development, regulatory affairs, manufacturing, and corporate development. The latter encompasses strategic planning, finance, and corporate partnering, along with support for government and private foundation grant writing. The fund's base of operations is nestled in the Westpark Corporate Center in Durham, North Carolina, which serves as a strategic hub for their sustained efforts in nurturing transformative life science ventures.